PSMA PET/CT in Detecting Esophageal Cancer and Hepatocellular Carcinoma. A Report of Two Cases
Prostate-specific membrane antigen (PSMA) PET/CT has improved the diagnosis, staging, and detection of recurrent and metastatic prostate cancer. Nevertheless, PSMA uptake has also been observed in non-prostatic conditions, which underscores the need to explore its broader applications and refine our understanding of its specificity in diverse clinical contexts. In cases of uptake in atypical locations, further workup is warranted to avoid premature conclusions of metastatic prostate disease. We report two cases of PSMA PET uptake: the first involves esophageal cancer, and the second details two synchronous malignancies-hepatocellular and esophageal cancer.
Authors
- Rami Chatta
- Hina Shah
- Saurabh Pallod
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Dana-Farber Cancer Institute (US)
Publication Details
- Journal
- Clinical Nuclear Medicine
- Published
- 2025-04-18
- DOI
- https://doi.org/10.1097/rlu.0000000000005901
- Citations
- 2
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 3.04